Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB

Neuroscientific Biopharmaceuticals — Broker Briefing Investor Webinar (November 2021)

13 slides from Neuroscientific Biopharmaceuticals's conference presentation, Nov 18, 2021

  1. Slide 1: Investor Webinar Presentation (ASX Announcement)

    ASX ANNOUNCEMENT 18 NOVEMBER 2021 INVESTOR WEBINAR PRESENTATION For personal use only NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) (“NeuroScientific” or “the company”) is pleased to advise shareholders and investors that the Company will be presenting as part of the free Broker Briefing Investo

  2. Slide 2: For personal use only

    active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body’s innate immune response to cell injury. Our preclinical research has established that EmtinBTM is highly specific and selective for its target receptor, safe and well tolerated at high

  3. Slide 3: Novel Drug Therapies for Neurodegenerative Conditions

    NOVEL DRUG THERAPIES FOR N E U R O D E G E N E R AT I V E For personal use only CONDITIONS Company Presentation November 2021

  4. Slide 4: Disclaimer

    DISCLAIMER For personal use only The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further ex

  5. Slide 5: Company Snapshot

    COMPANY SNAPSHOT For personal use only  Alzheimer’s disease – global prevalence 55M¹, high unmet need NOVEL LEAD COMPOUND  Multiple Sclerosis – US$27 billion treatment market ², unmet need for progressive MS  Glaucoma – 76M global prevalence³, 2nd lead cause of blindness ADDRESSING UNMET NEED IN

  6. Slide 6: Corporate Overview

    CORPORATE OVERVIEW (ASX: NSB) For personal use only CAPITAL STRUCTURE FINANCIALS ASX code NSB  IPO on ASX July 2018 (ASX: NSB) Shares on issue 143.5M  ~ $12.3M cash on hand Price (17/11/21) $0.36 Market cap $53M  Funded through to completion of current Phase I clinical program McRae Investments 1

  7. Slide 7: Leadership and Management

    LEADERSHIP AND MANAGEMENT For personal use only PAUL RENNIE, MBM, MSTC MATT LIDDELOW, MPHARM DR ANTON UVAROV, PhD, MBA STEPHEN QUANTRILL, MBA NON-EXECUTIVE CHAIRMAN MD + CEO EXECUTIVE DIRECTOR + CSO NON-EXECUTIVE DIRECTOR Founding and current CEO of Paradigm 14+ years experience commercialising Foun

  8. Slide 8: Markets

    MARKETS For personal use only  Neurodegenerative Disease market valued at ~USD 39.24 billion in 2020 is expected to witness a revenue of USD 44.90 billion in 20261  ~ 55 million people worldwide currently have dementia and there are ~ 10 million new cases every year; Alzheimer disease affects abou

  9. Slide 9: EmtinB Preclinical Data

    EMTINBTM PRECLINICAL DATA For personal use only  Nerve regeneration (including significant results in spinal injury model)  Reduction in neuroinflammation  Neuroprotection in cell survival models >90%  Proliferation of myelin in Multiple Sclerosis model  Slowed cognitive decline in Alzheimer’s

  10. Slide 10: EmtinB Development Plan

    EMTINBTM DEVELOPMENT PLAN For personal use only 2021 2022 Completion of Ph1 neurology Ph2 Neurology study neurology IND-enabling study Q4 2022 studies Q1 2022 Q4 2021 Complete ocular Ph1 glaucoma Ph2 glaucoma IND-enabling studies study study Q1 2022 H1 2022 Please note: Indicative timeline only and

  11. Slide 11: Partners and Collaborations

    PARTNERS AND COLLABORATIONS For personal use only NON-CLINICAL RESEARCH CLINICAL RESEARCH MANUFACTURING SCIENTIFIC ADVISORY Dr Frank Bonner, PhD FBTS Clin Prof. Allan Kermode MBBS MD FRACP FRCP Dr Peter Hnik, MD MHSc Former Director, Non-clinical R&D, Novartis Head, Neurology & Neurophysiology, SCG

  12. Slide 12: Summary Overview

    SUMMARY OVERVIEW For personal use only  Drug development company with advanced preclinical lead candidate - EmtinB™  Funded through to completion of Phase I program  Potential for multiple treatment indications (pipeline in a product)  Peptide based drug with advanced safety program, including n

  13. Slide 13: For More Information

    F O R M O R E I N F O R M AT I O N : For personal use only Matt Liddelow CEO & Managing Director ml@neuroscientific.com Alex Andrews Director of Operations aa@neuroscientific.com w w w. n e u r o s c i e n t i f i c . c o m 12

NeuroScientific Biopharmaceuticals — Broker Briefing Investor Webinar (November 2021) on 6ix